Plasma cardiotrophin-1 levels are associated with hypertensive heart disease: a meta-analysis.
Plasma cardiotrophin-1 levels are associated with hypertensive heart disease: a meta-analysis.
复制标题
血浆心蛋白1水平与高血压心脏病有关：荟萃分析。
DOI：
10.1111/jch.12376
复制
发表时间：
2014-09
期刊：
影响因子：
--
通讯作者：
Mani A
中科院分区：
文献类型：
--
作者：
Song K;Wang S;Huang B;Luciano A;Srivastava R;Mani A
Cardiotrophin-1 (CT-1) is a member of the interleukin-6 cytokine superfamily. Plasma CT-1 levels have been associated with heart failure and hypertension in small independent studies. Whether plasma CT-1 levels are associated with progression of hypertensive heart disease is poorly understood. We carried out a meta-analysis using published studies and electronic databases. Relevant data was extracted using standardized algorithms. Additional data were obtained directly from investigators when indicated. 18 studies were included that reported on association of CT-1 level with hypertension (n=8), cardiac hypertrophy (n=9) and heart failure (HF) (n=10). The serum levels of CT-1 were significantly higher in patients with hypertension (standard mean difference (SMD) =0.85, 95% CI 0.64–1.06 fmol/ml), left ventricular hypertrophy (SMD=0.88, 95% CI 0.60–1.17 fmol/ml), or HF (SMD=0.66, 95% CI 0.51–0.80 fmol/ml) compared to controls. Subgroup analysis revealed CT-1 levels to be highest in subjects with hypertension-induced hypertrophy with HF, followed by subjects with hypertension-induced LVH without HF (SMD=0.52, 95% CI 0.30–0.75 fmol/ml), subjects with hypertension without LVH (SMD=0.67, 95% CI 0.46–0.88 fmol/ml) as compared to normotensive subjects (SMD=0.74, 95% CI 10.45–1.04 fmol/ml). Increased plasma CT-1 levels are associated with the risk for heart failure in hypertensive patients. CT-1 may serve as a novel biomarker in determining prognosis in hypertensive patients.
